FR940610-1-00025 FR940610-1-00005 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Chapter I The Use of Immunohistochemical Devices in the Clinical Care of Patients; Notice of Public Workshop AGENCY: Food and Drug Administration, HHS. ACTION: Notice of public workshop. SUMMARY: The Food and Drug Administration (FDA) is announcing a public workshop to discuss the use of immunohistochemical devices in the clinical care of patients. In addition, FDA is interested in obtaining comments on the regulation of products used in immunohistochemical tests. DATES: The public workshop will be held on June 28 and 29, 1994, from 8:30 a.m. to 5 p.m. Those interested in making a formal presentation must submit a written request by June 20, 1994. ADDRESSES: The public workshop will be held at the Gaithersburg Hilton Hotel, 620 Perry Pkwy., Gaithersburg, MD. There is no registration fee, but interested persons should call the contact person listed below to preregister. Public participation is welcomed. Anyone wishing to make a formal presentation for inclusion in the workshop should submit a request accompanied by an outline of comments to Max Robinowitz (address listed below). FOR FURTHER INFORMATION CONTACT: Max Robinowitz, Center for Devices and Radiological Health (HFZ&hyph;440), Food and Drug Administration, 1390 Piccard Dr., Rockville, MD 20850, 301&hyph;594&hyph;3084, FAX 301&hyph;594&hyph;2360. SUPPLEMENTARY INFORMATION: Developments in the use of monoclonal antibodies in immunohistochemical devices which are used as an aid in the diagnosis and management of a variety of diseases, including neoplasms, make it appropriate to reassess FDA's regulation of these devices. Among the major topics scheduled for discussion are: (1) The role of immunohistochemical products in cancer diagnosis; (2) problems associated with the use of monoclonal antibodies in immunohistochemical techniques; (3) the role of training and proficiency; (4) proposed role of the Biological Stain Commission in technical certification of immunohistochemical antibodies; (5) discussion on a proposal for the classification of immunohistochemical antibodies as class II medical devices; and (6) draft points to consider and guidance for the regulation of immunohistochemical antibodies. Dated: June 7, 1994. Michael R. Taylor, Deputy Commissioner for Policy. [FR Doc. 94&hyph;14213 Filed 6&hyph;7&hyph;94; 4:36 pm] BILLING CODE 4160&hyph;01&hyph;F
